Trademark: 79155336
Word
VITROGRO
Status
Dead
Status Code
404
Status Date
Monday, October 8, 2018
Serial Number
79155336
Registration Number
4934476
Registration Date
Tuesday, April 12, 2016
Mark Type
4000
Filing Date
Thursday, August 28, 2014
Published for Opposition
Tuesday, January 26, 2016
Cancellation Date
Monday, October 8, 2018

Trademark Owner History
Tissue Therapies Limited - Original Registrant

Classifications
1 chemicals for use in science and industry, namely, biological tissue cultures other than for medical or veterinary purposes; biological products for use in science and industry, namely, a 3-dimensional living skin model comprising a de-cellurized de-epidermized dermis prepared from donor skin, for in vitro and in vivo scientific and research purposes and not for medical use, namely, investigating wound healing, pharmaceutics, toxicology, drug sensitivity, drug penetration and drug delivery, and recombinant therapeutic proteins for medical treatments; biochemicals, in the nature of proteins, for in vitro and in vivo scientific or research use, namely, vitronectin, fibronectin, insulin-like growth factor-I, insulin-like growth factor II, insulin-like growth factor binding proteins, epidermal growth factor, fibroblast growth factors, a combination of one or more of the foregoing proteins, portions of one or more of the foregoing proteins, and chimeric proteins containing any combination of the foregoing proteins or portions thereof; proteins for use in the manufacture of vaccines and bio-pharmaceuticals, namely, vitronectin, fibronectin, insulin-like growth factor-I, insulin-like growth factor II, insulin-like growth factor binding proteins, epidermal growth factor, fibroblast growth factors, a combination of one or more of the foregoing proteins, portions of one or more of the foregoing proteins, and chimeric proteins containing any combination of the foregoing proteins or portions thereof; kits containing biochemicals, namely, cell culture kits containing cell culture media and reagents for scientific and research use; biological products for use in science and industry, namely, biochemicals in the nature of proteins in raw form for cell culture and tissue engineering research, proteins for use in the clinical manufacture of vaccines, bio-pharmaceuticals, preparations for wound treatments, cell cultures and wound dressings; chemical reagents, namely, recombinant proteins for scientific and research use; chemicals for use in science and industry, namely, chemical preparations for cell culture for scientific and research use; chemical reagents, namely, biochemical reagents for scientific and research use and not for medical purposes; chemical reagents for scientific and research use and not for medical or veterinary purposes
5 biological preparations, namely, spray-on skin and cultured skin grafts for burn treatment and reconstructive ophthalmic or bladder surgeries, and recombinant therapeutic proteins for medical treatment of burns, hard to heal wounds, surgically created wounds, and incisions; pharmaceutical preparations for treating burns and venous ulcers, wounds in diabetics, non-diabetic chronic wounds, surgical wounds, and to speed healing and improve recovery and scarring after ophthalmic and cosmetic surgeries; veterinary preparations for horses, cattle, pigs, cats and dogs for treating burns and venous ulcers, wounds in diabetics, non-diabetic chronic wounds, surgical wounds, and to speed healing and improve recovery and scarring after ophthalmic and excisional surgeries; chemical preparations for cell culture for medical purposes, namely, for wound treatment; chemical reagents for medical use; biochemical reagents for medical use; recombinant proteins for medical use, namely, for use in cell culture autologous treatments, and for the treatment of burn and venous ulcer wounds, diabetic wounds, non-diabetic chronic wounds, surgical wounds, and to speed healing and improve recovery and scarring after surgery; biological preparations for medical use, namely, vitronectin, fibronectin, insulin-like growth factor-I, insulin-like growth factor II, insulin-like growth factor binding proteins, epidermal growth factor, fibroblast growth factor, a combination of one or more of the foregoing proteins, portions of one or more of the foregoing proteins, and chimeric proteins containing any combination of the foregoing proteins or portions thereof, for the treatment of burn and venous ulcer wounds, diabetic wounds, non-diabetic chronic wounds, surgical wounds, and to speed healing and improve recovery and scarring after surgery; biological tissue culture media for use in skin cell culture used for medical purposes; pharmaceutical preparations for skin care used for treating burns, venous ulcers, diabetic wounds, non-diabetic chronic wounds, surgical wounds, and to speed healing and improve recovery and scarring after ophthalmic and cosmetic surgeries, and for improving the appearance of wrinkles and skin defects; medical dressings, surgical dressings, wound care components, namely, wound and surgical dressings; surgical implants, namely, arterial grafts; drugs, namely, topical creams, gels and sprays for medical purposes for treating burns, venous ulcers, diabetic wounds, non-diabetic chronic wounds, surgical wounds, and to speed healing and improve recovery and scarring after ophthalmic and cosmetic surgeries; drugs, namely, topical creams, gels and sprays for veterinary purposes for use on horses, cattle, pigs, cats or dogs for treating burns, venous ulcers, diabetic wounds, non-diabetic chronic wounds, surgical wounds, and to speed healing and improve recovery and scarring after ophthalmic and excisional surgeries; vaccines
VITRO GROW

Trademark Events
May 3, 2019
Notification Of Effect Of Cancellation Of Intl Reg E-Mailed
May 3, 2019
Death Of International Registration
May 19, 2017
New Representative At Ib Received
Jul 28, 2016
Final Decision Transaction Processed By Ib
Jul 13, 2016
Final Disposition Notice Sent To Ib
Jul 13, 2016
Final Disposition Processed
Jul 12, 2016
Final Disposition Notice Created, To Be Sent To Ib
Apr 12, 2016
Registered-Principal Register
Jan 26, 2016
Official Gazette Publication Confirmation E-Mailed
Jan 26, 2016
Published For Opposition
Jan 22, 2016
Notification Processed By Ib
Jan 6, 2016
Notification Of Possible Opposition Sent To Ib
Jan 6, 2016
Notice Of Start Of Opposition Period Created, To Be Sent To Ib
Jan 6, 2016
Notification Of Notice Of Publication E-Mailed
Dec 22, 2015
Law Office Publication Review Completed
Dec 15, 2015
Assigned To Lie
Dec 2, 2015
Exparte Appeal Terminated
Dec 2, 2015
Approved For Pub - Principal Register
Oct 29, 2015
Teas/Email Correspondence Entered
Oct 29, 2015
Correspondence Received In Law Office
Oct 22, 2015
Assigned To Lie
Oct 1, 2015
Teas Request For Reconsideration Received
Oct 1, 2015
Ex Parte Appeal-Instituted
Oct 1, 2015
Jurisdiction Restored To Examining Attorney
Oct 1, 2015
Exparte Appeal Received At Ttab
Apr 7, 2015
Notification Of Final Refusal Emailed
Apr 7, 2015
Final Refusal E-Mailed
Apr 7, 2015
Final Refusal Written
Mar 11, 2015
Teas/Email Correspondence Entered
Mar 11, 2015
Correspondence Received In Law Office
Mar 11, 2015
Teas Response To Office Action Received
Feb 23, 2015
Attorney/Dom.Rep.Revoked And/Or Appointed
Feb 23, 2015
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Jan 8, 2015
Refusal Processed By Ib
Dec 19, 2014
Non-Final Action Mailed - Refusal Sent To Ib
Dec 19, 2014
Refusal Processed By Mpu
Dec 19, 2014
Non-Final Action (Ib Refusal) Prepared For Review
Dec 18, 2014
Non-Final Action Written
Dec 11, 2014
Assigned To Examiner
Nov 28, 2014
Application Filing Receipt Mailed
Nov 24, 2014
New Application Office Supplied Data Entered In Tram
Nov 21, 2014
Limitation From Original Application Entered
Nov 20, 2014
Sn Assigned For Sect 66a Subseq Desig From Ib

Trademark Alertz updated from USPTO on 2030-01-24